The earnings miss and declining cash position suggest continued dilution risk. Monitor upcoming IND filings for Wilson Disease and AATD as key catalysts, but near-term pressure from operating losses and arbitration costs may persist.
Price Chart
Executive Summary
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.25 by 12%, and collaboration revenue of $856K versus $884K estimate. Cash burn reduced runway to $149.2M, sufficient into 2027, but the earnings miss and declining revenue highlight ongoing pre-commercial challenges.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.28 vs consensus -$0.25 (12% miss)
- Collaboration revenue $856K vs $884K estimate (3.2% miss)
- Cash, cash equivalents, investments $149.2M at March 31, 2026, down from $191.4M at December 31, 2025
- Net loss $49.1M vs $51.9M same quarter prior year
- R&D expenses decreased to $34.1M from $40.6M; G&A increased to $17.4M due to arbitration costs
- Pipeline milestones: IND/CTA filings for PM577 (Wilson Disease) H1 2026 and PM647 (AATD) mid-2026; initial clinical data expected 2027
- CFO Svetlana Makhni appointed in April 2026
Financial Impact
EPS miss of $0.03 (12%) and revenue miss of $28K (3.2%); cash burn of ~$42M per quarter
Risk Factors
- Cash runway only into 2027; potential need for additional financing
- Arbitration-related legal expenses increasing G&A costs
- Delays in IND/CTA filings or clinical data could worsen sentiment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289924 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | Press Release | $2.90 | awaiting T+60 | — | $3.99 (+37.76%) |
Aug 6, 2026 11w ago | 8-K | $2.95 | awaiting T+60 | — | $3.99 (+35.42%) |
Jul 8, 2026 15w ago | 8-K | $4.62 $3.06 | ▼ −33.87% | ▼ −36.19% | $3.99 (−13.53%) |
Jun 18, 2026 18w ago | Press Release | $3.23 $3.18 | ▼ −1.55% | ▼ −3.44% | $3.99 (+23.68%) |
May 7, 2026 24w ago | 8-K | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.99 (−28.25%) |
May 7, 2026 24w ago | Press Release | $3.12 $2.81 | ▲ +9.79% | ▲ +13.62% | $3.99 (−28.25%) |
Apr 16, 2026 27w ago | 8-K | $3.67 $3.52 | ▼ −4.22% | ▼ −11.27% | $3.99 (+8.86%) |
Mar 3, 2026 34w ago | Press Release | $4.23 $3.30 | ▼ −21.99% | ▼ −32.30% | $3.99 (−5.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers